Welcome to our dedicated page for Spruce Biosciences news (Ticker: SPRB), a resource for investors and traders seeking the latest updates and insights on Spruce Biosciences stock.
Spruce Biosciences, Inc. (NASDAQ: SPRB) is a clinical-stage biopharmaceutical company dedicated to pioneering new therapies for rare endocrine disorders. The company's mission is to develop and commercialize novel treatments that address unmet medical needs within this specialized field.
Spruce Biosciences is currently advancing its primary product candidate, tildacerfont. This innovative therapy is being developed to serve as the first non-steroidal treatment designed to significantly improve disease management and lessen the dependency on steroids for patients with classic congenital adrenal hyperplasia (CAH). CAH is a genetic disorder affecting the adrenal glands, leading to an imbalance in hormone production. Tildacerfont aims to address this imbalance, offering a promising alternative for patients who have limited treatment options.
The company has made notable strides in its development programs, with ongoing clinical trials aiming to demonstrate the efficacy and safety of tildacerfont. These efforts are crucial in pushing the boundaries of current endocrine disorder treatments and providing new hope for those affected by these rare conditions.
In addition to its flagship product, Spruce Biosciences actively explores other potential therapies and partnerships to expand its impact in the field of endocrinology. The company’s financial health is supported by strategic investments and collaborations, ensuring robust progress towards its goals.
Spruce Biosciences’ commitment to addressing rare endocrine diseases positions it as a significant player in the biopharmaceutical industry. With a clear focus on innovation and patient care, the company continues to make meaningful advancements in medical science. Stay updated with the latest developments from Spruce Biosciences to learn more about its ongoing projects and clinical trials.
Spruce Biosciences (Nasdaq: SPRB) reported its Q2 2022 financial results, highlighting a net loss of $11.9 million, consistent with the previous year. The company achieved over 25% enrollment in both CAHmelia-203 and CAHmelia-204 studies. P.J. Ramtin has been appointed as Senior VP of Business Operations, bringing extensive industry experience. The patent portfolio for tildacerfont expanded with two new patents, extending exclusivity through 2038. Cash and investments totaled $99.1 million at quarter-end, with R&D expenses rising to $9.1 million as the company progresses clinical development.
Spruce Biosciences (NASDAQ: SPRB) announces participation in two investor conferences in June 2022. The Jefferies Healthcare Conference will take place from June 8-10, 2022, featuring a company presentation on June 8 at 4:00 PM ET. The JMP Securities Life Sciences Conference follows on June 15-16, 2022, highlighted by a fireside chat on June 16 at 11:30 AM ET. Webcasts of both events will be accessible via Spruce's investor relations website, with replays available for 30 days. Spruce is focused on therapies for rare endocrine disorders, including potential treatments for congenital adrenal hyperplasia.
Spruce Biosciences (NASDAQ: SPRB) announced an abstract acceptance for a poster presentation at the 104th Annual Meeting of the Endocrine Society (ENDO 2022) in Atlanta, GA, scheduled for June 11-14, 2022. The presentation will cover survey results assessing patient perceptions on glucocorticoid treatment for congenital adrenal hyperplasia (CAH). Key details include the session date of June 11, 2022, from 1:00 p.m. to 3:00 p.m. ET, presented by Dr. Chris N. Barnes. The company aims to develop non-steroidal therapies for CAH and is also exploring treatments for polycystic ovary syndrome (PCOS).
Spruce Biosciences (Nasdaq: SPRB) reported progress in its CAHmelia-203 study for adult classic congenital adrenal hyperplasia (CAH), achieving 25% enrollment and expects topline data by H2 2023. The company amended its debt facility with Silicon Valley Bank for a $10 million credit line, reducing interest rates. R&D expenses rose to $8.5 million, while total operating expenses increased to $11.7 million, resulting in a net loss of $11.8 million for Q1 2022. The patent portfolio for tildacerfont has also expanded, enhancing market exclusivity.
Spruce Biosciences (NASDAQ: SPRB) announced its participation in two upcoming investor conferences in May 2022. The first event is the RBC Capital Markets Global Healthcare Conference on May 17-18, featuring a fireside chat on May 17 at 10:00 a.m. ET. The second event is the H.C. Wainwright Global Investment Conference from May 23-26, with a company presentation on May 25 at 4:00 p.m. ET. Interested investors can access webcasts via the company’s investor relations website. Spruce focuses on therapies for rare endocrine disorders.
Spruce Biosciences, Inc. (NASDAQ: SPRB) has appointed Libbie Mansell, Ph.D., M.B.A., R.A.C., as its Chief Regulatory and Quality Officer. Dr. Mansell will lead global regulatory affairs and quality strategy as the company advances its drug tildacerfont for rare endocrine disorders, including congenital adrenal hyperplasia and polycystic ovary syndrome. With over 30 years of experience in regulatory affairs, she aims to enhance Spruce's pipeline of treatments for significant unmet medical needs. CEO Javier Szwarcberg highlights her extensive expertise as a critical addition to the team.
Spruce Biosciences, Inc. (Nasdaq: SPRB) reports its fourth quarter and annual financial results for 2021, highlighting progress in developing treatments for rare endocrine disorders. The company anticipates topline safety data from its Phase 2 Pediatric Classic CAH study by 1H 2023. As of December 31, 2021, Spruce had cash and investments of $121.4 million, expected to fund operations into Q2 2024. R&D expenses increased to $30.7 million from $23.9 million in 2020. The net loss for 2021 was $42.3 million, compared to $29.5 million the previous year.
Spruce Biosciences, Inc. (NASDAQ: SPRB) has appointed Dr. Will Charlton as Chief Medical Officer following the departure of Dr. Rosh Dias. Dr. Charlton, with over 15 years in clinical research and experience in rare disease drug development, will lead Spruce's clinical strategies, particularly focusing on tildacerfont, aimed at treating classic congenital adrenal hyperplasia and polycystic ovary syndrome.
CEO Javier Szwarcberg expressed confidence in Dr. Charlton's expertise, anticipating significant advancements in therapies for rare endocrine disorders, which have seen no new treatments in nearly 50 years.
Spruce Biosciences (NASDAQ: SPRB), a late-stage biopharmaceutical company, announced its participation in two virtual investor conferences in March 2022. The Cowen 42nd Annual Health Care Conference will occur from March 7-9, featuring a company presentation on March 9 at 11:10 a.m. ET. The Oppenheimer 32nd Annual Healthcare Conference will take place from March 15-17, with a fireside chat on March 16 at 8:00 a.m. ET. Webcasts of these events will be accessible on the company's investor relations website.
Spruce Biosciences, Inc. (NASDAQ: SPRB) announces participation in the SVB Leerink 11th Annual Global Healthcare Conference on February 17, 2022, at 5:00 PM EST. CEO Javier Szwarcberg and CFO Samir Gharib will engage in a virtual fireside chat. This company focuses on developing therapies for rare endocrine disorders, particularly its candidate tildacerfont for classic congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS). Interested parties can access the live webcast on the company's investor relations website, with an archived replay available for 30 days.
FAQ
What is the current stock price of Spruce Biosciences (SPRB)?
What is the market cap of Spruce Biosciences (SPRB)?
What is Spruce Biosciences, Inc. focused on?
What is tildacerfont?
What are classic congenital adrenal hyperplasia (CAH) and its symptoms?
How is Spruce Biosciences contributing to medical science?
What is the significance of tildacerfont in treating CAH?
Are there ongoing clinical trials for tildacerfont?
How does Spruce Biosciences support its financial health?
What partnerships does Spruce Biosciences have?
Where can I find the latest news about Spruce Biosciences?
What makes Spruce Biosciences a significant player in its industry?
